Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28620928 | 0.85 | ATM (0.39) | ITGB3ITGA2BFOLH1ATMTDP1 | |
| SCHEMBL26616331 | 0.85 | FOLH1 (0.46) | GNPATITGB3ITGA2BFOLH1KMT2A | |
| SCHEMBL20450527 | 0.84 | SLC6A5 (0.50) | ITGB3ITGA2BFOLH1KMT2A | |
| SCHEMBL20450528 | 0.84 | SLC6A5 (0.50) | ITGB3ITGA2BFOLH1KMT2A | |
| SCHEMBL13069729 | 0.84 | CTSK (0.50) | ITGB3ITGA2BCTSKCTSSATM | |
| SCHEMBL9196011 | 0.84 | CTSK (0.50) | ITGB3ITGA2BCTSKCTSSATM | |
| SCHEMBL24204924 | 0.82 | L3MBTL1 (0.45) | CTSKATMTDP1KMT2APOLB | |
| SCHEMBL11785105 | 0.82 | L3MBTL1 (0.39) | FOLH1ATMTDP1KMT2APOLB | |
| SCHEMBL20710289 | 0.82 | L3MBTL1 (0.45) | CTSKATMTDP1KMT2APOLB | |
| SCHEMBL18438966 | 0.82 | CTSK (0.43) | CTSKCTSSATMTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | claimed |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | claimed |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2018-09-25 | — | — | US | claimed |
| WO-2017189715-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | claimed |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-12-27 | — | — | US | disclosed |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2018-09-25 | — | — | US | disclosed |
| WO-2017189715-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | NORTHWESTERN UNIVERSITY (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305998-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | GNPAT 2461/4885ITGB3 1377/4885ITGA2B 1344/4885 |
| US-10081668-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | GNPAT 2512/4885ITGB3 1477/4885ITGA2B 1422/4885 |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | GNPAT 2512/4885ITGB3 1477/4885ITGA2B 1422/4885 |
| US-20180371060-A1 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION | VEGFA, LITAF, HDGF | GNPAT 2461/4885ITGB3 1377/4885ITGA2B 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.